Fusen Pharmaceutical Company Limited (01652) said the group expects to record a profit attributable to shareholders in the range of RMB63 million to RMB75 million for the year ended 31 December 2020, which represented an increase of approximately 21% to 44% as compared with the profit attributable to shareholders of approximately RMB52 million for the year ended 31 December 2019.
The expected increase in profit was mainly due to the increase in the sales of Shuanghuanglian Oral Solutions, the group's major product, as a result of increased market demand.
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情
